SOURCES SOUGHT
66 -- Digital PCR System
- Notice Date
- 4/13/2012
- Notice Type
- Sources Sought
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, Maryland, 20857-0001
- ZIP Code
- 20857-0001
- Solicitation Number
- 1101651
- Archive Date
- 5/5/2012
- Point of Contact
- Sondea Blair, Phone: 8705437469
- E-Mail Address
-
sondea.blair@fda.hhs.gov
(sondea.blair@fda.hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS FOR MARKET RESEARCH PURPOSES ONLY, NOT A REQUEST FOR PROPOSAL OR SOLICITATION. The U.S. Food and Drug Administration (FDA) is seeking small business concerns, including veteran-owned small businesses, service-disabled veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women owned small businesses. The following information is provided to assist the FDA in conducting Market Research to identify potential small business concerns for this effort: The FDA's Center for Biologics Evaluation and Research (CBER) in Rockville, MD is seeking small business concerns capable of meeting the FDA's requirement for a Digital Polymerase Chain Reaction (PCR) System to continue the ongoing research of Differentiation and Maturity of Human Stem Cells. Specifications The Digital PCR system must measure target DNA molecules with precision and accuracy. The Digital PCR system must be inclusive of the following: -Generator -Reader -2X4.5mL Buffer Control Kit -5x1 ml tubes for use in sample preparation -Oil for use with generator -Oil for use with reader -Buffer control kit for use with PCR system -2 x 1 ml, 200 x 20 µl reactions, 2x RT-ddPCR mix -Generator Cartridges and Gaskets -Laptop Computer, Software, and associated component consumables. The generator must partition sample into thousands of nano-liter-sized droplets, each with an independent PCR reaction. Upon PCR on thermo cycler, droplets must be able to be streamed in single file on the reader to count positive and negative reactions. The Digital PCR system must be able to deliver an absolute count of the number of the target DNA sequences for applications that include copy number variation, mutation detection, and gene expression analysis. The Digital PCR System must be capable of achieving a linear dynamic range of more than 4 orders of magnitude for DNA quantification. The associated North American Industry Classification System (NAICS) Code is 334516, Analytical Laboratory Instrument Manufacturing; Small Business Size Standards is 500 in number of employees. Interested small business concerns must respond with capability statements which are due in person, by postal mail, fax or email to the point of contact listed below on or before April 20, 2012 by 09:00 hours (Central Time in Jefferson, Arkansas) at the Food and Drug Administration, FDA/OO/OFBA/OAGS/DAP, Attn: Sondea Blair, 3900 NCTR Road, HFT-320, Jefferson, AR 72079-9502. Reference FDA101651. Respondents should supply: -Business name, DUNS number, business address, business website, business size status (i.e., SB, VOSB, SDVOSB, HUBZone SB, SDB, WOSB), point of contact name, mailing address (if different from business address), phone number and email address. -Indicate whether you are the manufacturer of the product put forth for consideration and if not the manufacturer, identify your position in the supply chain and identity the actual manufacturer. -Capability statements must provide enough information to determine if the company can meet the requirement and be not longer than 5 pages excluding set-aside certifications. -Informational Pricing -Prior experience over the last three (3) years in furnishing and supporting PCR systems to include institution and point of contact name, phone number and email address for each institution identified. For information regarding this market survey, please contact Sondea Blair sondea.blair@fda.hhs.gov. The government is not responsible for locating or securing any information, which is not identified in the response. Disclaimer and Important Notes. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in FedBizOpps. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/FDA/DCASC/1101651/listing.html)
- Place of Performance
- Address: US Food and Drug Administration, Center for Biologics Evaluation and Research, 8800 Rockville Pike, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02721939-W 20120415/120413235150-bfcb0ec9b92e53411819d3ef88a2b71a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |